FDA Revisits Botanical Drugs

11:14 AM ETDeveloping

Health Desk

In Short: The FDA is reassessing its approach to botanical drugs as part of its ongoing efforts to improve drug regulation.

Drug Fact Sheet Header 2 (Drug Enforcement Administration) — Photo: Drug Enforcement Administration / Wikimedia Commons (Public domain)

The U.S. Food and Drug Administration (FDA) is currently reviewing its policies on botanical drugs, a move aimed at enhancing the regulatory framework for these medications.

This reassessment comes as part of the FDA's broader strategy to address persistent challenges in the pharmaceutical industry, including the barriers to the use of clozapine and the potential of pig kidneys in bridging the gap for organ transplant patients.

What's confirmed

What's still developing

Test your knowledge with our new weekday mini crossword Today, we look at the FDA’s interest in botanical drugs, the persistent barriers to clozapine use, and the ways in which pig kidneys could bridge patients to human transplants.

Sources

STATlink